Aivo Biosciences

Executive Summary

Aivo Biosciences is a preclinical-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is developing novel small molecule therapeutics targeting central nervous system (CNS) disorders, with a core focus on M1 muscarinic receptor agonism. Its lead program is aimed at treating schizophrenia and psychosis, leveraging the M1 receptor's role in cognitive function and positive symptoms. Aivo plans to expand into other neuropsychiatric and neurodegenerative diseases, such as Alzheimer's disease. As a private company with limited public information, Aivo benefits from the strong scientific rationale behind M1 agonism, which has shown promise in modulating cholinergic signaling without the peripheral side effects of non-selective muscarinic agonists. However, the company faces typical preclinical risks including drug optimization, toxicity, and the challenge of CNS penetration. Aivo's progress will depend on successful IND-enabling studies and eventual clinical validation. Given its early stage, the company is not yet generating revenue and likely relies on venture funding. The exectutive summary reflects a cautious optimism based on the unmet need in schizophrenia and the potential of selective M1 agonists to offer improved efficacy and tolerability over existing treatments.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program in Schizophrenia40% success
• Q3 2026Presentation of Preclinical Data at Major CNS Conference70% success
• Q4 2026Series A or Additional Funding Round50% success